Status: Recruiting
Exploratory Clinical Study of Second-generation CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in Treating Paediatric B Cell-related Autoimmune Diseases
Evaluating the efficacy and safety of anti-CD19/BCMA CAR-NK Cells in Paediatric B cell-related autoimmune diseases
Participants needed: 12
Trial details
Phase: Early Phase 1Age: 3+Biological sex: AllType: InterventionalSponsor: The Children's Hospital of Zhejiang University School of MedicineUpdated: Feb 3, 2026Locations: 1
Eligibility criteria
Informed consent: The participant (and guardian if the participant is a minor) m... [+38]
Subjects with known severe allergic reactions, hypersensitivity, contraindicatio... [+15]